Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Telomerase RNA component interacting RNase (TRIR) is a protein-coding gene recognized for its role as an exoribonuclease that participates in the processing of the 3' end of telomerase RNA. It exhibits both 3'-5' and 5'-3' exonuclease activities, capable of cleaving all four unpaired RNA nucleotides, with higher cleavage efficiency for purine bases. TRIR is important in RNA catabolic processes, including the degradation and processing of ribosomal RNA (rRNA). It is classified molecularly as an enzyme, specifically an exoribonuclease, and has been annotated under several aliases, including C19orf43 and fSAP18. Disease associations are limited and mainly include rare conditions such as binocular vision disease and Tinea unguium. As of current knowledge, there are no established drugs targeting TRIR, and its use as a biomarker or notable safety concerns in therapeutic contexts have not been documented in available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Telomerase RNA component interacting RNase (TRIR).